Factor Xa inhibitor
Factor Xa inhibitor, Ornithodoros moubata .
Factor Xa inhibitor (X Roman ten ) describes in one term the mechanism of action of the active ingredients from the class of anticoagulants , the mode of operation of which is to inhibit the activated coagulation factor X , a central component of blood clotting . Other common names of the drug group are anti-Xa , factor Xa inhibitors , FXa inhibitors and - for the direct inhibitors - Xabane .
Active ingredients
Direct inhibitors:
- Apixaban (trade name: Eliquis)
- Edoxaban (trade name: Lixiana)
- Otamixaban (development discontinued in 2013)
- Rivaroxaban (trade name: Xarelto)
Indirect inhibitors:
- Tinzaparin (trade name: Innohep)
- Certoparin (trade name: Mono-Embolex)
- Dalteparin (trade name: Fragmin)
- Enoxaparin (trade name: Clexane)
- Fondaparinux (trade name: Arixtra)
- Nadroparin (trade name: Fraxiparin)
- Reviparin (trade name: Clivarin, Clivarodi)
Individual evidence
- ↑ More details on failure of Sanofi's otamixaban at ESC ( Memento of the original from December 3, 2013 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. , www.pharmatimes.com, accessed December 1, 2013
